Citation Tools
Clinical and epidemiological research
Extended report
A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis